Copy to clipboard 
Keith Pfeil, Executive Vice President, Chief Operating Officer and Chief Financial Officer of Globus Medical, was appointed President and Chief Executive Officer of the company effective July 18, 2025. Daniel Scavilla has resigned as President and Chief Executive Officer to pursue another opportunity as President and CEO of Dentsply Sirona.
Additionally, Kyle Kline, Senior Vice President of Finance, has been appointed Senior Vice President and Chief Financial Officer.
“We are excited to appoint Keith Pfeil as our next President and Chief Executive Officer. Keith brings a sharp strategic mindset and a results-orientated leadership style with a clear understanding of how to drive performance across an organization,” said David C. Paul, Globus Medical Founder and Executive Chairman. “His manner and approach demonstrate strong cultural alignment with the Globus philosophy, and we look forward to him leading us as Globus continues to execute its strategy of becoming the pre-eminent musculoskeletal technology company in the world.”
Mr. Pfeil began his career with Globus in 2019 as Senior Vice President and Chief Financial Officer. In 2024, he was named Executive Vice President, Chief Operating Officer and Chief Financial Officer and has played a vital role in executing the company’s strategy.
“I’m deeply grateful to David and the Board for this opportunity and want to thank Dan for his mentorship and partnership throughout my journey thus far at Globus,” commented Mr. Pfeil. “I’ve had the opportunity to grow with this team over the past 6 years, and I am excited to carry forward our strong culture of purpose, innovation and teamwork that will meaningfully impact the lives of patients as we move ahead.”
“I’m thrilled to welcome Kyle Kline to our executive leadership team as the next CFO of Globus,” commented Mr. Pfeil. “After spending almost 10 years with Deloitte, Kyle joined Globus in 2017 as the Assistant Controller and has continuously taken on increased financial responsibility over his eight-year career. He and I have worked closely together, and he’s been a valued and trusted partner of mine. The combination of his integrity, passion and knowledge of our business makes him the right choice to lead Globus as its next CFO.”
“On behalf of the Board and all the employees of Globus, I want to thank Dan for his leadership and commitment to Globus over the past 10 years,” commented Mr. Paul. “Dan has helped us with our vision of transitioning Globus from an implant and instrument provider to a musculoskeletal technology and solutions provider. We are grateful for his contributions and wish him continued success in his next chapter.”
“It has been an honor to lead Globus Medical and be part of this exceptional team,” Mr. Scavilla said. “I look forward to watching the company’s continued success as Keith leads Globus into its next chapter and know that he will drive meaningful impact to the company as it moves ahead. I’m proud to have been part of Globus.”
Globus Medical became the second-largest spine company in the world during Mr. Scavilla’s tenure as he led the company through its acquisition of NuVasive. Despite the received wisdom in spine that large acquisitions don’t work, Globus’ pro-forma growth rate since the deal has compared favorably with the overall spine industry.
Globus Medical also announced today its preliminary sales results for the second quarter ending June 30, 2025. The company anticipates 2Q25 sales to be approximately $745.3 million, an as-reported increase of 18.4% over the second quarter of 2024, inclusive of its acquisition of Nevro. Base business growth for the quarter was approximately 3.3%.
Source: Globus Medical, Inc.
Keith Pfeil, Executive Vice President, Chief Operating Officer and Chief Financial Officer of Globus Medical, was appointed President and Chief Executive Officer of the company effective July 18, 2025. Daniel Scavilla has resigned as President and Chief Executive Officer to pursue another opportunity as President and CEO of Dentsply...
Keith Pfeil, Executive Vice President, Chief Operating Officer and Chief Financial Officer of Globus Medical, was appointed President and Chief Executive Officer of the company effective July 18, 2025. Daniel Scavilla has resigned as President and Chief Executive Officer to pursue another opportunity as President and CEO of Dentsply Sirona.
Additionally, Kyle Kline, Senior Vice President of Finance, has been appointed Senior Vice President and Chief Financial Officer.
“We are excited to appoint Keith Pfeil as our next President and Chief Executive Officer. Keith brings a sharp strategic mindset and a results-orientated leadership style with a clear understanding of how to drive performance across an organization,” said David C. Paul, Globus Medical Founder and Executive Chairman. “His manner and approach demonstrate strong cultural alignment with the Globus philosophy, and we look forward to him leading us as Globus continues to execute its strategy of becoming the pre-eminent musculoskeletal technology company in the world.”
Mr. Pfeil began his career with Globus in 2019 as Senior Vice President and Chief Financial Officer. In 2024, he was named Executive Vice President, Chief Operating Officer and Chief Financial Officer and has played a vital role in executing the company’s strategy.
“I’m deeply grateful to David and the Board for this opportunity and want to thank Dan for his mentorship and partnership throughout my journey thus far at Globus,” commented Mr. Pfeil. “I’ve had the opportunity to grow with this team over the past 6 years, and I am excited to carry forward our strong culture of purpose, innovation and teamwork that will meaningfully impact the lives of patients as we move ahead.”
“I’m thrilled to welcome Kyle Kline to our executive leadership team as the next CFO of Globus,” commented Mr. Pfeil. “After spending almost 10 years with Deloitte, Kyle joined Globus in 2017 as the Assistant Controller and has continuously taken on increased financial responsibility over his eight-year career. He and I have worked closely together, and he’s been a valued and trusted partner of mine. The combination of his integrity, passion and knowledge of our business makes him the right choice to lead Globus as its next CFO.”
“On behalf of the Board and all the employees of Globus, I want to thank Dan for his leadership and commitment to Globus over the past 10 years,” commented Mr. Paul. “Dan has helped us with our vision of transitioning Globus from an implant and instrument provider to a musculoskeletal technology and solutions provider. We are grateful for his contributions and wish him continued success in his next chapter.”
“It has been an honor to lead Globus Medical and be part of this exceptional team,” Mr. Scavilla said. “I look forward to watching the company’s continued success as Keith leads Globus into its next chapter and know that he will drive meaningful impact to the company as it moves ahead. I’m proud to have been part of Globus.”
Globus Medical became the second-largest spine company in the world during Mr. Scavilla’s tenure as he led the company through its acquisition of NuVasive. Despite the received wisdom in spine that large acquisitions don’t work, Globus’ pro-forma growth rate since the deal has compared favorably with the overall spine industry.
Globus Medical also announced today its preliminary sales results for the second quarter ending June 30, 2025. The company anticipates 2Q25 sales to be approximately $745.3 million, an as-reported increase of 18.4% over the second quarter of 2024, inclusive of its acquisition of Nevro. Base business growth for the quarter was approximately 3.3%.
Source: Globus Medical, Inc.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
